60 Degrees Pharmaceuticals develops and commercializes medicines for vector-borne disease, led by ARAKODA® (tafenoquine), an FDA-approved malaria prevention drug for adults. Company news commonly covers ARAKODA access and marketing channels for U.S. travelers, including telehealth and prescription-savings arrangements, as well as financial results and capital-market actions tied to its Nasdaq-listed common stock and warrants.
Updates also address tafenoquine development beyond malaria prophylaxis, including reports from studies in relapsing babesiosis, and work involving Australian Chestnut Extract, castanospermine and celgosivir-related research for non-prescription or infectious-disease applications. The company’s announcements frequently combine product availability, regulatory interactions, license arrangements, clinical data and corporate-structure matters such as reverse stock split actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.